Skip to main content

Market Overview

Certara Appoints Drayton T. Virkler as Chief Commercial Officer


PRINCETON, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company's global commercial strategy and execution and expand the business development team.

"I am pleased to welcome Drayton as our new Chief Commercial Officer," said William F. Feehery, Ph.D., CEO of Certara. "His role will be vital to advancing our business growth strategy of global expansion and deepening our partnerships with biopharmaceutical clients. Drayton's extensive leadership experience and commercial knowledge will be invaluable as we continue increasing adoption of biosimulation and other technologies to transform the drug development process."

Mr. Virkler was most recently at IQVIA for a decade, where he served as Vice President and Global Head of Sales for the Real World Solutions Global Business Unit. He was responsible for driving all sales teams and marketing activities in the business unit, delivering revenue growth each year. He has held other commercial leadership roles at IQVIA, including helming the global account team for a top 5 global pharmaceutical company and leading business development in the U.S., Canada, and in the Asia Pacific region. Previously, Mr. Virkler held leadership roles at Talecris Plasma Resources, now part of Grifols, and GlaxoSmithKline.

"I am excited to join Certara's executive team and build out the commercial arm of this dynamic organization," said Mr. Virkler. "Certara is leading the charge in delivering cutting-edge biosimulation tools and innovative solutions to top pharmaceutical companies and biotechs to improve drug development. I am looking forward to getting Certara's software and tech-driven services to more drug developers to advance new life-saving medicines worldwide."

Mr. Virkler holds a bachelor's degree in chemistry from Washington and Lee University and an MBA from Duke University's Fuqua School of Business.

About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Certara Contact:
Jieun Choe

Media Contact:
Ariane Lovell
Finn Partners

Investor Relations Contact:
David Deuchler
Gilmartin Group

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at